Pulmonary Arterial Hypertension (PAH) Infused/Inhaled Enrollment Form



Fax Referral To: 1-877-943-1000 Email Referral To: PAH.Faxes@CVSHealth.com

| PATIENT IN | IFORMATION (Comp | olete or include demo | | ittilig a Kelellai | | | |
|-----------------|---------------------------|---------------------------------------|-------------------|----------------------|-------------------------------|----------|----------|
| _ | | _ | | DOB: | Gender: 🗌 | Male | ☐ Female |
| Address: | | | | | le: | | |
| Preferred Cont | act Methods: Phon | ie (to primary # provi | ided below) 🔲 | Text (to cell # prov | rided below) 🗌 Email (t | to email | provided |
| below) | | | | | | | |
| | | | | | e, you are consenting to | | |
| | | _ | | | s), account, and health o | | |
| | | | | | nacy will attempt to con | | |
| Email: | | | | | Primary Language: | | |
| | | | | | patient: | | |
| | ER INFORMATION | · , , | | - · · | | | |
| Prescriber's Na | ıme: | | State Licens | se #: | | | |
| | | | | | | | |
| Address: | | | City, State, Z | ZIP Code: | | | |
| | | | | | ntact's Phone: | | |
| INSURANC | | | | | rm, if available (front and b | | |
| = | S AND CLINICAL IN | ., . | | | , | • | |
| _ | E | | tient 🗌 Office [| Other: | | | |
| - | | _ Omp to: 1 a | | | | | |
| Data of Diagna | o-10): sis: | | | | | | |
| | | naian | □ 107 00 D | Jaconom / Llunomto | saion Unoposified | | |
| | ry Pulmonary Hypertei | | | | nsion, Unspecified | : | |
| | ndary Pulmonary Arter | 1al Hypertension | | | nolic Pulmonary Hyperte | ension | |
| | menger's Syndrome | | ☐ 127.89 Of | ther Specified Puli | nonary Disease | | |
| ☐ Other Code | : | Description | | | | | |
| Patient Clinica | | | | | | | |
| | t Association (NYHA) I | | tion: 🔲 I 📙 II | ∐ III ∐ IV | | | |
| | Distance: | | | | | | |
| - | ntly on another therap | | ertension? 📙 ` | Yes ∐ No | | | |
| • | drug(s): | | | | | | |
| - | _lb/kg Height: | _ | | | | _ | |
| Attach copies | of: History and Phys | sical Right Heart C | Catheterization | Calcium Chann | el Blocker Statement | Echoca | rdiogram |
| Nursing: No | ot Needed 🗌 Pre-hosp | oital/Pre-home Teachi | ing 🗌 In-hospit | tal Teaching 🔲 N | ırsing Follow-up | | |
| Start of care d | ate: Ni | umber of visits: | | | | | |
| Prostacyclin R | eferral Information: | | | | | | |
| = | es below to designat | e which items are in | cluded in this f | ax: | | | |
| ☐ PAH diagnos | sis and ICD-10 code (de | signated on PAH refer | rral form) | | | | |
| Is Medicare Par | t B the primary insuranc | ce for this referral? | Yes 🗌 No | | | | |
| Clinical docu | mentation | | | | | | |
| ☐ Current H | &P (within 6 months); D | ate of H&P: | | | | | |
| ☐Right Hear | t Catheterization (RHC) | ; Check below if inclu | ded in the RHC r | eport | | | |
| ☐ Mean P | A Pressure (or systolic/ | 'diastolic) > 25 mmHg | at rest or > 30 m | nmHg with exertion | | | |
| ☐ Cardiad | Output | Cardiac Ind | lex | | | | |
| ☐ Pulmor | ary Vascular Resistanc | e 🔲 Pulmonary | Capillary Wedge | e Pressure (or LVED | P) < 15 mmHg | | |
| Echocardi | iogram | | | | | | |
| | Channel Blocker stateme | · · · · · · · · · · · · · · · · · · · | | | | | |
| | | | | | -proportion with the seco | | |
| | , valvular heart disease, | , lung disease, sarcoic | dosis and other c | o-morbidities, exce | pt for the ones listed in W | √HO Gro | up I |
| category | | | | | | | |

Phone: 1-877-242-2738

Pulmonary Arterial Hypertension (PAH) Infused/Inhaled Enrollment Form

Tyvaso, Tyvaso DPI, Ventavis, Flolan, Epoprostenol (Generic Flolan)

| Patient Name: | | | Prescriber InformationPatient Phone: | | |
|---|---|--|--|---|--|
| Prescriber Name: | | Prescriber Phone: | | | |
| PRESCRIPTION | NINFORMATION | | | | |
| - NHALED PRODUC | | | | | |
| MEDICATION | STRENGTH | D | OSE & DIRECTIONS | QUANTITY/REFILI | |
| ☐ Tyvaso (treprostinil) Starter Kit ☐ Tyvaso Refill Kit | | ☐ Start with 3 breaths (18 mcg) four times daily. Increase by 3-4 breaths at 1-2 week intervals, if tolerated, until the target dose of 9 breaths (54 mcg) four times daily. ☐ Other: | | Quantity: 28-day supply Refills: | |
| ☐ Tyvaso DPI (Treprostinil) | Tyvaso DPI Titration Kit 16 mcg/32 mcg 16 mcg/32 mcg/48 mcg Tyvaso DPI Maintenance Kit 16 mcg | | · | Tyvaso DPI Titration Kit Quantity: 28-day supply Refills: 0 | |
| | □ 32 mcg □ 48 mcg □ 64 mcg □ 80 mcg: 32 mcg/48 mcg □ cevery week as tolerate □ Inhale one breath p □ Other: | | d to selected target dose. er cartridge 4 times daily | Tyvaso DPI Maintenance Kit Quantity: 28-day supply Refills: | |
| ☐ Ventavis (iloprost) Inhalation Solution | NA | Please complete a Ventavis enrollment form and indicate CVS Specialty as your preferred pharmacy provider. The form may be accessed at www.4ventavis.com or by calling 1-866-228-3546. | | Quantity: 0 Refills: 0 | |
| NFUSED THERAPIE | S: | | | | |
| MEDICATION | STRENGTH | | OOSE & DIRECTIONS | QUANTITY/REFILL | |
| ☐ Flolan (epoprostenol) for injection | 0.5 mg vial 1.5 mg vial Sterile diluent for Flolan | IV infusion continuous over 24 hours Initial dose: ng/kg/min. Titrate by ng/kg/min every days until goal of ng/kg/min achieved. Discharge dose: ng/kg/min Concentration: ng/mL | | Quantity: One-month suppl of drug and supplies. | |
| | pH 12 sterile diluent for Flolan | Pump: 2 CADD-Lega CVC Care: Dressing change eve | Dosing weight: kg/lb Refills: | | |
| Patient is interested in pa | 1 23 1 | P SIGNATURE NOT ALLOWED | Ancillary supplies and kits provide | ed as needed for administration | |
| | 6 PRESCRIBER SIGNAT | TURE REQUIRED (ST | AMP SIGNATURE NOT ALLOWED) | | |
| DAW / May Not Substitu | | | May Substitute / Product Selection Permitted / Substitution Permissible | | |
| Prescriber's Signature:Date: | | | Prescriber's Signature: | Date: | |

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

Pulmonary Arterial Hypertension (PAH) Infused/Inhaled Enrollment Form

Remodulin, Treprostinil (Generic Remodulin), Veletri, Epoprostenol (Generic Veletri)

| | Please | Complete Patient and I | Prescriber Information | |
|--|--|--|--|--|
| atient Name: | | Patient DOB: | Patient Phone: | |
| rescriber Name: | | | Prescriber Phone: | |
| PRESCRIPTIO | N INFORMATION | | | |
| NFUSED THERAF | PIES CONTINUED: | | | |
| MEDICATION | STRENGTH | | | UANTITY/REFILLS |
| Remodulin (treprostinil) for injection 1 mg/mL, 20 mL vial 2.5 mg/mL, 20 mL vial 5 mg/mL, 20 mL vial 10 mg/mL, 20 mL vial 10 mg/mL, 20 mL vial | | SC continuous over 24 ho Initial dose: ng/kg/ days until goal of ng/kg/ Change infusion site every Palliative med PRN Pump: 2 CADD-MS3 pumps* | Quantity: One-month supply of drug and supplies. Dosing weight: kg/lb Refills: | |
| ☐ Treprostinil (Generic Remodulin) | 1 mg/mL, 20 mL vial 2.5 mg/mL, 20 mL vial 5 mg/mL, 20 mL vial 10 mg/mL, 20 mL vial | ☐ IV infusion continuous over Initial dose: ng/kg/days until goal of ng_biluent: Check one (Sterile dichecked) ☐ 0.9% NaCl for injection ☐ Epoprostenol Sterile dilue Pump: ☐ 2 CADD-Legacy PtCVC Care: | er 24 hours min. Titrate byng/kg/min every | Quantity: One-month supply of drug and supplies. Dosing weight: kg/lb Refills: |
| ☐ Veletri (epoprostenol) for injection | ☐ 0.5 mg vial ☐ 1.5 mg vial | ☐ IV infusion continuous over Initial dose: ng/kg/days until goal of ng/kg/discharge dose: ng/kg/Diluent: Check one (0.9% Soc ☐ 0.9% NaCl for injection Pump: ☐ 2 CADD-Legacy PCVC Care: ☐ Dressing change every | Quantity: 30-day supply of drug and supplies. Dosing weight: kg/lb Refills: | |
| ☐ Epoprostenol (Generic Veletri) | 3 3 | | | Quantity: 30-day supply of drug and supplies. Dosing weight: kg/lb Refills: |
| Patient is interested in p | | STAMP SIGNATURE NOT ALLOWED | Ancillary supplies and kits provided as need | ed for administration |
| | 6 PRESCRIBER SIG | NATURE REQUIRED (ST | AMP SIGNATURE NOT ALLOWED) | |
| • | / Brand Medically Necessary / Do N | lot Substitute / No Substitution / | May Substitute / Product Selection Permitted / | |
| DAW / May Not Substi | tute nature: | Data | Substitution Permissible Prescriber's Signature: | Date: |
| | iaiuf t. | บลเย: | riescriber's Signature: | pate: |

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature. CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissenination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.